Toll-like receptor 7

Toll-like receptor 7 (TLR7) is a protein that in humans is encoded by the TLR7 gene. TLR7 is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. TLR7 is known to recognize single-stranded RNA (ssRNA) from viruses, leading to the activation of immune responses.

Structure and Function

TLR7 is primarily expressed in plasmacytoid dendritic cells, B cells, and macrophages. It is located intracellularly, within endosomal compartments, where it can recognize viral ssRNA. Upon recognition of ssRNA, TLR7 triggers signaling pathways that result in the production of type I interferons (IFNs), particularly IFN-α, and other pro-inflammatory cytokines. This is crucial for the control of viral infections and for initiating adaptive immune responses.

Signaling Pathway

The signaling pathway of TLR7 involves several key molecules. Upon ligand recognition, TLR7 recruits the adaptor protein MyD88 (myeloid differentiation primary response 88), leading to the activation of IRAK4 (IL-1 receptor-associated kinase 4) and TRAF6 (TNF receptor-associated factor 6). This cascade ultimately activates NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and IRF7 (interferon regulatory factor 7), which are transcription factors that promote the expression of type I IFNs and other inflammatory cytokines.

Clinical Significance

TLR7 has been implicated in the pathogenesis of various diseases, including viral infections, autoimmune diseases, and cancer. Its role in recognizing viral ssRNA makes it a critical component of the antiviral immune response. However, aberrant activation of TLR7 can contribute to autoimmune diseases, such as systemic lupus erythematosus (SLE), where self-RNA might be mistakenly recognized as viral, leading to inappropriate immune activation. In cancer, TLR7 agonists are being explored as potential immunotherapies, as they can induce strong antitumor immune responses.

Agonists and Antagonists

Several synthetic agonists of TLR7 have been developed for therapeutic purposes, including imiquimod and resiquimod, which are used topically to treat certain skin cancers and viral infections by enhancing the immune response. Conversely, antagonists of TLR7 are being investigated for the treatment of autoimmune diseases, aiming to reduce the inappropriate immune activation.

Conclusion

TLR7 is a critical component of the innate immune system, playing a key role in the defense against viral infections and in the initiation of adaptive immunity. Its involvement in various diseases highlights the importance of understanding TLR7 signaling pathways for the development of novel therapeutic strategies.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian